ensysce.com - צמיחת הכנסות ב-12 חודשים נגררים ENSC

FDA grants to combat the opioid crisis are driving Ensysce Biosciences (ENSC), and the GURU.Markets platform displays the YoY sales growth for the last four quarters, where the value stands at 37.90. The strategy is based on the implementation of TAAP and MPAR systems to eliminate overdoses. However, risks are linked to dependence on regulatory approval and potential secondary offerings to fund trials.

The commercialization of the unique TAAP technology for creating safe opioids defines the scaling potential of Ensysce Biosciences (ENSC). This process is reflected through the calculation of daily revenue changes over a rolling year, allowing investors to assess real demand for innovation by bypassing quarterly gaps and analyzing the annual growth rate of sales revenue (rolling period).